Celularity names Rick Gonzalez Chief Commercial Officer, advances longevity and cenplacel-L focus

Celularity Inc

Rick Gonzalez appointed CCO effective May 29, 2026, reporting to Chairman & CEO Robert Hariri.
Gonzalez has 20+ years biotech experience; previously CCO at Alume Biosciences, CEO at Navidea.
Company sharpens focus on longevity, regenerative medicine; cenplacel-L sees physician demand in Florida.
Out-licensed biomaterials to NexGel for up to $30M, reducing liabilities by ~$13M (previously announced).

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Rick Gonzalez

Chief Commercial Officer

CELU · Celularity Inc

Effective: 2026-05-29
Filed: June 3, 2026, 5:22 PM ET

On May 29, 2026, Celularity Inc. (“Celularity”) appointed Rick Gonzalez as Chief Commercial Officer of Celularity.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Rick Gonzalez was appointed as Chief Commercial Officer at Celularity Inc.

Action: appointed
Role: Chief Commercial Officer

Exact text from the filing

On May 29, 2026, Celularity Inc. (“Celularity”) appointed Rick Gonzalez as Chief Commercial Officer of Celularity.

View on SEC.gov

Celularity Inc filing history →

Source: SEC EDGAR

accession 0001493152-26-027132

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.